Lakeshore Financial Planning Inc. Invests $327,000 in Pfizer Inc. (NYSE:PFE)

Lakeshore Financial Planning Inc. purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, Holdings Channel.com reports. The fund purchased 12,343 shares of the biopharmaceutical company’s stock, valued at approximately $327,000.

A number of other large investors have also modified their holdings of PFE. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer in the fourth quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer in the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer in the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer in the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Truist Financial decreased their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Down 0.2 %

Shares of PFE opened at $26.17 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The stock has a market capitalization of $148.29 billion, a price-to-earnings ratio of 18.56, a PEG ratio of 0.64 and a beta of 0.61. The stock has a 50 day moving average price of $26.18 and a 200 day moving average price of $27.07.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.